Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 49–72 of 164
Insilico Medicine and Liquid AI are developing specialized AI foundation models to accelerate drug discovery by improving molecular prediction, biological activity forecasting, and compound design. This partnership demonstrates how computational efficiency in scientific AI can reduce timelines for therapeutic development while making tools accessible across the research community.
A two-year study of 958 adults aged 70+ found that daily multivitamin use slowed biological aging markers measured through epigenetic clocks, with the effect most pronounced in participants showing accelerated aging. While the slowdown was modest—measured in months rather than years—the consistent effect across multiple aging biomarkers suggests multivitamins may influence cellular-level processes relevant to healthspan rather than lifespan extension.
Cognision360 consolidates neurobiomarker data collection and analysis for CNS clinical trials through automated workflows and standardized integration of EEG, sleep, eye tracking, wearables, and cognitive assessments. The platform addresses fragmentation in multi-site studies and accelerates regulatory pathways by improving data integrity and reducing manual processing errors.
Insilico Medicine and Eli Lilly have established a drug discovery partnership leveraging AI to accelerate identification and development of oral therapeutics across multiple disease areas. This collaboration represents a shift in pharmaceutical R&D methodology toward computational drug discovery, with potential implications for reducing development timelines and costs in longevity-related therapeutic areas.
AI-driven bioengineering platforms are accelerating protein design and drug discovery by computational screening of millions of proteins and billions of compounds annually, reducing traditional wet-lab timelines. This technological shift reshapes how therapeutic candidates are identified and optimized, with governments globally investing multibillion-dollar programs to scale these capabilities.
Researchers mapped functional consequences of hundreds of mutations in RNU4-2, a 145-base non-coding RNA gene within the spliceosome, linking splicing dysfunction to neurodevelopmental disorders affecting approximately 100,000 individuals globally. This work establishes a systematic framework for interpreting non-coding variants and refines genomic diagnosis beyond association to functional mechanism.
Amydis has secured $2.5 million in Phase 2 NIH funding to develop a non-invasive eye-imaging technology that detects TDP-43, a protein biomarker present in over 97% of ALS cases. Early detection through a simple retinal scan could compress the current 9-12 month diagnostic timeline and enable earlier therapeutic intervention in a disease where time is critical.
Verge Labs has established a frontier AI platform trained on VergeDB, a proprietary multimodal dataset of over 12,000 brain transcriptomes and matched molecular, clinical, and imaging data from living patients. The platform's disease targets have validated at 83 percent accuracy against experimental confirmation, with its first AI-discovered CNS asset advancing through Phase 1b trials, positioning machine learning as a substantive tool for accelerating central nervous system drug development.
Curve Biosciences appointed hepatologist Dr. Amit Singal as Chief Medical Officer to advance clinical translation of its circulating DNA diagnostic platform for early organ dysfunction detection. The move signals a strategic shift from technology development toward embedding blood-based diagnostics into existing clinical workflows, beginning with liver disease where earlier intervention can measurably alter patient outcomes.
Technogym and Google Cloud are integrating generative AI into fitness platforms to shift from episodic workout protocols toward continuous, anticipatory health management scaled across populations. This partnership pairs four decades of physiological performance data with advanced language models to support adherence—a persistent barrier to preventive health outcomes—while embedding technology into the daily behavioral substrate where health decisions actually occur.
BioAge is advancing BGE-102, an oral NLRP3 inflammasome inhibitor, into Phase 2 trials for atherosclerotic cardiovascular disease and retinal disease based on Phase 1 data showing tolerability and reductions in inflammatory markers. NLRP3 inhibition represents a mechanistic approach to reducing systemic inflammation implicated in multiple age-related conditions.
Givaudan and Haut.AI are demonstrating AI-powered skin visualization tools at an industry conference, allowing consumers to preview how active ingredients affect visible skin parameters. The partnership emphasizes personalized prediction of ingredient effects through generative simulation technology.
C2N Diagnostics has launched blood-based Alzheimer's testing in South Korea through a partnership with BeauBrain Healthcare. The PrecivityAD2 test detects amyloid pathology with 91% accuracy and offers a less invasive, more accessible alternative to PET imaging for identifying cognitive impairment earlier in disease progression.
AliveCor's Kardia 12L portable AI-powered ECG system has gained regulatory approval in Vietnam, enabling distributed cardiac diagnostics in a country where cardiovascular disease accounts for 33% of deaths. The device reduces acquisition time by approximately 30% and simplifies the testing process, addressing both access barriers and workflow bottlenecks in healthcare systems managing high patient volumes.
Astronauts exposed to spaceflight show accelerated epigenetic aging markers during mission, with partial recovery after return to Earth. This natural experiment reveals how extreme environmental stress—microgravity, radiation, isolation—affects the molecular clock and provides insight into aging acceleration mechanisms relevant to terrestrial health conditions.
Insilico Medicine's AI-designed drug candidate MEN2501 has advanced to first-in-human dosing in a Phase 1 trial, triggering an $5 million milestone payment and validating generative AI's capacity to compress drug discovery timelines from years to months. The molecule targets chromosomal instability in solid tumors—a mechanism relevant to cellular aging—and represents a proof-of-concept for AI-driven identification of therapeutic candidates.
Helical has raised $10 million to build a shared computational platform that integrates AI models with reproducible workflows for drug discovery, addressing the critical gap between predictive capability and implementable decision-making in pharmaceutical R&D. The platform consolidates fragmented AI predictions into a unified system where results are traceable, validated, and actionable at scale.
Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.
Xsensio has secured $7 million in Series A funding to advance a wearable biosensing platform that continuously monitors multiple biomarkers in interstitial fluid, initially targeting early detection of organ dysfunction in acute care settings. Real-time access to biochemical data at the point of care represents a shift from periodic laboratory measurement to continuous physiological surveillance, with potential implications for earlier clinical intervention.
Argo Biopharma has dosed the first patient in a Phase 2b trial of BW-20829, an siRNA therapy targeting elevated Lipoprotein(a) and atherosclerotic cardiovascular disease. Lp(a) represents a genetically determined cardiovascular risk factor resistant to conventional interventions, making this advance relevant to a significant gap in current therapeutic options for reducing disease burden and extending healthspan.
AI implementation in long-term care for older people risks compromising care quality when framed narrowly around workforce efficiency rather than centered on care outcomes and ethical implications. A care-centric approach requires understanding how automation affects the complex relational and systemic structures that support health across the lifespan.
Analysis of spontaneous speech patterns—including acoustic features, linguistic markers, and speech rate—can identify physical functional decline in aging populations with accuracy comparable to formal physical assessments. This approach enables remote, scalable detection of mobility and strength deficits without requiring in-person testing.
AliveCor's Kardia 12L is a handheld, AI-assisted device that captures 12-lead ECG-quality cardiac data with simplified hardware and reduced setup time. The CE-marked system detects 35 cardiac conditions and reduces testing time by approximately one-third, extending hospital-grade diagnostic capacity into primary care, rural, and home settings.
Artificial intelligence is accelerating neuroprotective drug discovery across target identification, molecular design, and clinical optimization, with hundreds of millions in venture funding flowing into AI-driven neuroscience companies and major pharma investing in AI-enabled development platforms. This shift compresses timelines for bringing neuroprotective agents to market and expands the addressable therapeutic space for neurodegeneration.
